Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab as add-on therapy in eosinophilic COPD with frequent exacerbations
jRCT2031220621Completed
- Sponsor
- GSK
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Mepolizumab arm with Placebo arm (2 arms). Started Feb 2023; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031220621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220621.